SCHEMBL2056510

SCHEMBL2056510

CCC(=O)N(c1ccc(F)cc1)C1CCN(CCc2ccccc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 12/20 0.85
OPRD1 P41143 5/20 0.85
OPRK1 P41145 5/20 0.85
SLC22A1 O15245 1/20 0.85
NR1I2 O75469 1/20 0.85
ABCB1 P08183 1/20 0.85
CHRM1 P11229 1/20 0.85
DRD2 P14416 1/20 0.85
ADRA2B P18089 1/20 0.85
ADRA2C P18825 1/20 0.85
CHRM3 P20309 1/20 0.85
MAOA P21397 1/20 0.85
DRD4 P21917 1/20 0.85
MAOB P27338 1/20 0.85
ADRA1A P35348 1/20 0.85
HRH1 P35367 1/20 0.85
ADRA1B P35368 1/20 0.85
DRD3 P35462 1/20 0.85
CHRNA4 P43681 1/20 0.85
SLC6A3 Q01959 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13284174 0.96 OPRM1 (0.85) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL27642639 0.92 OPRM1 (0.95) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL916599 0.92 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL8804 0.92 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1NR1I2
SCHEMBL18623766 0.91 OPRM1 (0.75) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL28383546 0.91 OPRM1 (0.98) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL4321837 0.91 OPRM1 (0.98) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL22637301 0.91 OPRM1 (0.98) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL18249370 0.91 OPRM1 (0.98) OPRM1OPRD1OPRK1SLC22A1NR1I2
Fentanyl SCHEMBL4324385 0.91 OPRM1 (0.98) OPRM1OPRD1OPRK1SLC22A1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2024172892-A1 PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION Zymeron Corporation (US) 2024-08-22 WO claimed
WO-2024173482-A2 COMPOSITIONS AND METHODS RELATED TO APTAMER-BASED SENSORS NORTH CAROLINA STATE UNIVERSITY (US) 2024-08-22 WO claimed
US-11579110-B2 Aptamer-based sensors for detection of fentanyl opioids THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-02-14 US claimed
US-20220291163-A1 APTAMER-BASED SENSORS FOR DETECTION OF FENTANYL OPIOIDS THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2022-09-15 US claimed
US-11408850-B2 Aptamer-based sensors for detection of fentanyl opioids THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2022-08-09 US claimed
EP-3560484-A1 ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION G.L. Pharma GmbH (AT) 2019-10-30 EP claimed
EP-3423034-B1 ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION G L PHARMA GMBH (AT) 2019-07-10 EP claimed
EP-3423034-A1 ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION G.L. Pharma GmbH (AT) 2019-01-09 EP claimed
EP-3210596-A1 ABUSE-DETERRENT PHARMACEUTICAL COMPOSITION G.L. Pharma GmbH (AT) 2017-08-30 EP claimed
EP-3129028-A1 PHARMACEUTICAL COMPOSITIONS Charleston Laboratories, Inc. (US) 2017-02-15 EP claimed
US-20150313846-A1 PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM FLAMEL IRELAND LIMITED (IE) 2015-11-05 US claimed
WO-2015157738-A1 PHARMACEUTICAL COMPOSITIONS CHARLESTON LABORATORIES, INC. (US) 2015-10-15 WO claimed
US-9023400-B2 Prolonged-release multimicroparticulate oral pharmaceutical form FLAMEL TECHNOLOGIES (FR) 2015-05-05 US claimed
US-8652529-B2 Anti-misuse microparticulate oral pharmaceutical form FLAMEL TECHNOLOGIES (FR) 2014-02-18 US claimed
US-8445023-B2 Anti-misuse microparticulate oral pharmaceutical form FLAMEL TECHNOLOGIES (FR) 2013-05-21 US claimed
US-20100092553-A1 ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM FLAMEL TECHNOLOGIES (FR) 2010-04-15 US claimed
US-20070224129-A1 Anti-misuse microparticulate oral pharmaceutical form FLAMEL TECHNOLOGIES, INC. (FR) 2007-09-27 US claimed
US-20260086062-A1 IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2026-03-26 US disclosed
WO-2007093642-A2 MICROPARTICULATE PHARMACEUTICAL FORMS RESISTANT TO IMMEDIATE RELEASE OF THE ACTIVE PRINCIPLE IN THE PRESENCE OF ALCOHOL FLAMEL TECHNOLOGIES (FR) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260086062-A1 IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS EBPL, ADA, XBP1 OPRM1 1242/4885OPRD1 2597/4885OPRK1 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.